Our company news

Smooth Drug Development achievements in China Smooth Drug Development opened a representative office in China and plans to continue its contribution to the development of therapeutics in China and assist Chinese clients enter EAEU and EC markets

We are working on the following new projects: • We were awarded with a bioequivalence trial of Ketorolac.

We are working on the following new projects: • We signed the contract for the trial of III phase in inflammatory and degenerative diseases of the musculoskeletal system.

We are working on the following new projects: We signed the contracts for the III phase Nimesulide trials of in dorsopathy and postoperative pain.

We are working on the following new projects: • We signed a contract for medical writing activities with Fabomotizole.

We are working on the following new projects: • We were awarded with two contracts for full-service support in bioequivalence trials with Rivaroxaban 10 mg and 20 mg.

We are working on the following new projects: • We were awarded with a contract for medical writing activities with pelubiprofen

We are working on the following new projects: • We signed two contracts for data management services for bioequivalence trials with Paroxetine and Desloratadine.

We are working on the following new projects: Smooth signed a contract for a bioequivalence trial with Rivaroxaban.

The International Day of Clinical Research is celebrated on May 20

We are working on the following new projects: • Smooth is starting a new project in acute nasopharyngitis with our long-term Russian client.

We are working on the following new projects: • We were awarded with Rebamipide trial.

We are working on the following new projects: Smooth signed a contract for a trial with Fabomotizole. We were awarded with a medical writing project with INN Budesonide.

We are working on the following new projects: • We were awarded with two phase IV full-service trials of Nimesulide. • We signed four new contracts for BE trials with our Russian sponsor